Sugi Predict

Sugi Predict / Compounds / SCHEMBL605127

SCHEMBL605127

SCHEMBL605127

c1ccc(Oc2cccc(CN3CCC(OCc4c[nH]cn4)CC3)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.49
▸ ALDH1A1 P00352 4/20 0.49
▸ HPGD P15428 2/20 0.49
▸ HTT P42858 2/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ CCR8 P51685 4/20 0.48
▸ TRPV6 Q9H1D0 1/20 0.48
▸ LMNA P02545 3/20 0.44
▸ DRD3 P35462 2/20 0.44
▸ SIGMAR1 Q99720 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ DRD4 P21917 1/20 0.44
▸ TMEM97 Q5BJF2 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ FAAH O00519 2/20 0.44
▸ CACNA1F O60840 1/20 0.43
▸ CHRM2 P08172 1/20 0.43
▸ ADRB1 P08588 1/20 0.43
▸ DRD2 P14416 1/20 0.43
▸ SLC6A2 P23975 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL605914 0.92 DRD2 (0.46) KDM4EALDH1A1TDP1CCR8FAAH
SCHEMBL604428 0.92 DRD2 (0.46) KDM4EALDH1A1TDP1CCR8SIGMAR1
SCHEMBL5793572 0.87 MEN1 (0.47) KDM4EALDH1A1HTTCCR8LMNA
SCHEMBL5765258 0.84 DRD4 (0.46) DRD3SIGMAR1DRD4TMEM97
SCHEMBL603848 0.84 DRD4 (0.46) ALDH1A1DRD3SIGMAR1DRD4TMEM97
SCHEMBL603140 0.84 CARM1 (0.53) ALDH1A1DRD3SIGMAR1SMN1; SMN2DRD4
SCHEMBL606084 0.84 ACHE (0.51) DRD3SIGMAR1DRD4TMEM97SLC6A2
SCHEMBL603549 0.84 CARM1 (0.53) KDM4EALDH1A1HTTDRD3SIGMAR1
SCHEMBL2567141 0.83 NPC1 (0.58) KDM4EALDH1A1HTTSMN1; SMN2OPRL1
SCHEMBL5487632 0.82 CARM1 (0.51) ALDH1A1DRD3SIGMAR1DRD4TMEM97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185163-A1 Imidazol derivatives of piperidine as histamine antagonists ASTRAZENECA AB (SE) 2007-08-09 — — US claimed
EP-1651634-A1 IMIDAZOL DERIVATIVES OF PIPERIDINE AS HISTAMINE ANTAGONISTS AstraZeneca AB (SE) 2006-05-03 — — EP claimed
WO-2005014579-A1 IMIDAZOL DERIVATIVES OF PIPERDINE AS HISTAMINE ANTAGONISTS ASTRAZENECA AB (SE) 2005-02-17 — — WO claimed
US-10195195-B2 Selective histamine H4 receptor antagonists for the treatment of vestibular disorders INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2019-02-05 — — US disclosed
EP-3378476-A1 H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS Sensorion (FR) 2018-09-26 — — EP disclosed
US-9688989-B2 H4 receptor inhibitors for treating tinnitus SENSORION (FR) 2017-06-27 — — US disclosed
US-20170056397-A1 SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2017-03-02 — — US disclosed
EP-3130376-A1 SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2017-02-15 — — EP disclosed
US-9526725-B2 Selective histamine H4 receptor antagonists for the treatment of vestibular disorders INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2016-12-27 — — US disclosed
EP-2382013-B1 SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) 2016-07-13 — — EP disclosed
US-20150176010-A1 H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS SENSORION (FR) 2015-06-25 — — US disclosed
US-20120039913-A1 Selective Histamine H4 Receptor Antagonists for the Treatment of Vestibular Disorders INSERM (institut National de la Sante de la Recher Medicale) (FR) 2012-02-16 — — US disclosed
EP-2382013-A1 SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2011-11-02 — — EP disclosed
WO-2010072829-A1 SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2010-07-01 — — WO disclosed
US-20070185163-A1 Imidazol derivatives of piperidine as histamine antagonists ASTRAZENECA AB (SE) 2007-08-09 — — US disclosed
US-20070185163-A1 Imidazol derivatives of piperidine as histamine antagonists ASTRAZENECA AB (SE) 2007-08-09 — — US disclosed
US-20070185163-A1 Imidazol derivatives of piperidine as histamine antagonists ASTRAZENECA AB (SE) 2007-08-09 — — US disclosed
EP-1651634-A1 IMIDAZOL DERIVATIVES OF PIPERIDINE AS HISTAMINE ANTAGONISTS AstraZeneca AB (SE) 2006-05-03 — — EP disclosed
WO-2005014579-A1 IMIDAZOL DERIVATIVES OF PIPERDINE AS HISTAMINE ANTAGONISTS ASTRAZENECA AB (SE) 2005-02-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185163-A1 Imidazol derivatives of piperidine as histamine antagonists HRH2, HRH1, HRH4 KDM4E 1228/4885ALDH1A1 1130/4885HPGD 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.